




PTO/SB/21 (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/712,425
	Filing Date	November 13, 2003
	First Named Inventor	Lee
	Art Unit	1631
	Examiner Name	Lin, Jerry
Total Number of Pages in This Submission	Attorney Docket Number	EPT-001C1

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	- PTO Form SB/08a/b citing references A6-A31, B4-B11, and C14-C55
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	- Certificate of First Class Mailing
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	- Return Receipt Postcard
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	GOODWIN PROCTER LLP	
Signature		
Printed name	Randall D. Morin	
Date	October 3, 2006	Reg. No. 58,312



PTO/SB/17 (07-06)

Approved for use through 01/31/2007. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).		Complete if Known	
FEE TRANSMITTAL For FY 2005		Application Number	10/712,425
		Filing Date	November 13, 2003
		First Named Inventor	Lee
		Examiner Name	Lin, Jerry
		Art Unit	1631
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Attorney Docket No.	EPT-001C1
TOTAL AMOUNT OF PAYMENT	(\$) 180.00		

METHOD OF PAYMENT (check all that apply)	
<input checked="" type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify): _____	
<input type="checkbox"/> Deposit Account	Deposit Account Number: <u>07-1700</u> Deposit Account Name: <u>Goodwin Procter LLP</u>
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
	FILING FEES		SEARCH FEES		EXAMINATION FEES		
		Small Entity		Small Entity		Small Entity	
Application Type	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fees Paid (\$)
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES							
						Small Entity	
Fee Description						Fee (\$)	Fee (\$)
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
Total Claims		Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims		
_____ - 20 = _____		x _____	=	0.00	Fee (\$)		Fee Paid (\$)
					_____		0.00
HP = highest number of total claims paid for, if greater than 20.							
Indep. Claims		Extra Claims	Fee (\$)	Fee Paid (\$)			
_____ - 3 = _____		x _____	=	0.00			
HP = highest number of independent claims paid for, if greater than 3.							
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof		Fee (\$)	Fee Paid (\$)		
_____ - 100 = _____	/50	_____ (round up to a whole number) x _____		=	0.00		
4. OTHER FEE(S)							
Non-English Specification, \$130 fee (no small entity discount)				Fees Paid (\$)			
Other (e.g., late filing surcharge): Submission of a Supplemental Information Disclosure Statement				180.00			

SUBMITTED BY			
Signature		Registration No. (Attorney/Agent)	58,312
Name (Print/Type)	Randall D. Morin	Telephone	(617) 570-1000
		Date	October 3, 2006

LIBC/2851048.1



IFU/\$1

PATENT
Attorney Docket No. EPT-001C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Lee *et al.*
SERIAL NO.: 10/712,425 GROUP NO.: 1631
FILING DATE: November 13, 2003 EXAMINER: Lin, Jerry
TITLE: PROTEOME EPITOPE TAGS AND METHODS OF USE
THEREOF IN PROTEIN MODIFICATION ANALYSIS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with 37 C.F.R. 1.98(a)(2), only copies of the foreign patent documents and non-patent publications are enclosed.

In addition, Applicants wish to inform the Examiner about the following U.S. patent applications and the contents of their file wrappers, including all Office actions issued therein:

1. U.S.S.N. 10/436,549, entitled "Unique Recognition Sequences and Methods of Use Thereof in Protein Analysis," filed on May 12, 2003, and published as 2004/0038307 A1, on February 26, 2005 (A28 in attached form PTO/SB/08a/b).
2. U.S.S.N. 10/773,032, entitled "Proteome Epitope Tags and Methods of Use Thereof in Protein Modification Analysis," filed on February 5, 2004, and published as 2005/0069911 A1, on March 31, 2005 (A29 in attached form PTO/SB/08a/b).
3. U.S.S.N. 11/066,967, entitled "Proteome Epitope Tags and Methods of Use Thereof in Protein Modification Analysis," filed on February 5, 2005, and published as 2006/0014212 A1, on January 19, 2006 (A30 in attached form PTO/SB/08a/b).

10/10/2006 RMEBRAHT 00000075 10712425

01 FC:1806

180.00 0P

4. U.S.S.N. 11/249,847, entitled "Unique Recognition Sequences and Methods of Use Thereof in Protein Analysis," filed on October 13, 2005, and published as 2006/0035270 A1 on February 16, 2006 (A31 in attached form PTO/SB/08a/b).

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☒ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☒ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,



Randall D. Morin
Attorney for Applicants
Goodwin Procter LLP
Exchange Place
Boston, Massachusetts 02109
Customer No. 051414

Date: October 3, 2006
Reg. No.: 58,312

Tel. No.: (617) 570-1657
Fax No.: (617) 523-1231

VER 11/03
2851178



PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/712,425	
			Filing Date	November 13, 2003	
			First Named Inventor	Lee	
			Art Unit	1631	
			Examiner Name	Lin, Jerry	
Sheet	1	of	3	Attorney Docket Number	EPT-001C1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A6	4,478,744	10/23/1984	Mezei <i>et al.</i>	
	A7	6,113,897	9/5/2000	Dano <i>et al.</i>	
	A8	6,225,047	5/1/2001	Hutchens	
	A9	2004/0229284	11/18/2004	Luciw <i>et al.</i>	
	A10	2005/0214304	9/29/2005	Pastan <i>et al.</i>	
	A11	5,955,317	9/21/1999	Suzuki <i>et al.</i>	
	A12	2003/0054408 A1	3/20/2003	Ravi <i>et al.</i>	
	A13	5,708,155	1/13/1998	Potter <i>et al.</i>	
	A14	5,763,158	6/9/1998	Bohannon <i>et al.</i>	
	A15	5,790,155	8/4/1998	Usui <i>et al.</i>	
	A16	5,798,155	8/25/1998	Yanagawa <i>et al.</i>	
	A17	5,872,234	2/16/1999	Bandman <i>et al.</i>	
	A18	5,961,923	10/5/1999	Nova <i>et al.</i>	
	A19	6,261,569	7/17/2001	Comis <i>et al.</i>	
	A20	6,420,125	7/16/2002	Fledelius <i>et al.</i>	
	A21	2002/0042386 A1	4/11/2002	Rosen <i>et al.</i>	
	A22	2002/0055186 A1	5/9/2002	Barry <i>et al.</i>	
	A23	2002/0081617 A1	6/27/2002	Buranda <i>et al.</i>	
	A24	2002/0110843 A1	8/15/2002	Dumas	
	A25	2003/0028330 A1	2/6/2003	Cheng <i>et al.</i>	
	A26	2003/0032039 A1	9/12/2002	Cunningham <i>et al.</i>	
	A27	2003/0044862 A1	3/6/2003	Giaccia <i>et al.</i>	
	A28	2004/0038307 A1	02/26/2004	Lee <i>et al.</i>	
	A29	2005/0069911 A1	03/31/2005	Lee <i>et al.</i>	
	A30	2006/0014212 A1	01/19/2006	Benkovic <i>et al.</i>	
	A31	2006/0035270 A1	02/16/2006	Lee <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B4	DE 40 23 945	1/30/1992		(trans. abstract only)	X
	B5	EP 0 337 057	1/23/1989		(trans. abstract only)	X
	B6	EP 0 267 355	3/27/1987		(trans. abstract only)	X
	B7	WO 05/50223	6/2/2005	Epitome Biosystems, Inc.		
	B8	WO 05/78453	8/25/2005	Epitome Biosystems, Inc.		
	B9	JP 07-285999 A	10/31/1995	Prima Meat Packers Ltd.		X
	B10	WO 02/06834 A	1/24/2002	Pointilliste, Inc.		
	B11	WO 99/39210 A	8/5/1999	Miller		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/712,425	
			Filing Date	November 13, 2003	
			First Named Inventor	Lee	
			Art Unit	1631	
			Examiner Name	Lin, Jerry	
Sheet	2	of	3	Attorney Docket Number	EPT-001C1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C14	Arnheiter <i>et al.</i> (1981) "Physiochemical and Antigenic Properties of Synthetic Fragments of Human Leukocyte Interferon," <i>Nature</i> 294: 278-80.	
	C15	Arnon (1991) "Synthetic Peptides as the Basis for Vaccine Design," <i>Molecular Immunology</i> 28(3) 209-215.	
	C16	Barbas III <i>et al.</i> (1991) "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site," <i>PNAS USA</i> 88: 7978-7982.	
	C17	Barry <i>et al.</i> (2003) "Competitive Assay Formats for High-Throughput Affinity Arrays," <i>J. Biomol. Screen.</i> *(3): 257-263.	
	C18	Borreback (2000) "Antibodies in Diagnostics - From Immunoassays to Protein Chips," <i>Immunology Today</i> 21(8): 379-381.	
	C19	Chames <i>et al.</i> (2000) "Antibody Engineering and its Applications in Tumor Targeting in Intracellular Immunization," <i>FEMS Microbiology Letters</i> 189: 1-8.	
	C20	Chou <i>et al.</i> (1974) "Prediction of Protein Conformation," <i>Biochemistry</i> 13(2): 222-245.	
	C21	Devereux <i>et al.</i> (1984) "A Comprehensive Set of Sequence Analysis Programs for the VAX," <i>Nucleic Acids Research</i> 12 (1) 387-395.	
	C22	Erali <i>et al.</i> (1996) "ELISA for Thyroglobin in Serum: Recovery Studies to Evaluate Autoantibody Interference and Reliability of Thyroglobin Values," <i>Clinical Chemistry</i> 42: 766-770.	
	C23	European Supplementary Search Report for EPSN 03808371, completed 06/01/2006, dated 06/12/2006 (7 pages).	
	C24	Harper <i>et al.</i> (1998) Two-Dimensional Gel Electrophoresis, Unit 10.4, <i>Current Protocols in Protein Science</i> , pgs. 10.4.1 to 10.4.36.	
	C25	Haupt <i>et al.</i> (1998) "Plastic Antibodies: Developments and Applications," <i>Trends Biotech.</i> 16: 468-475.	
	C26	Hellmold <i>et al.</i> (2002) "Identification of End Points Relevant to Detection of Potentially Adverse Drug Reactions," <i>Toxicology Letters</i> 127: 239-243.	
	C27	Hemminki <i>et al.</i> (1998) "Fine Tuning of an Anti-Testosterone Antibody Binding Site by Stepwise Optimisation of the CDRs," <i>Immunotechnology</i> 4: 59-69.	
	C28	Hennig (1998) "WinPep-ein Programm zur Analyse von Aminosäuresequenzen," <i>Biospektrum</i> 4(5): 49-50.	
	C29	Hoogenboom <i>et al.</i> (1998) "Antibody Phage Display Technology and its Applications," <i>Immunotechnology</i> 4: 1-20.	
	C30	Hoogenboom <i>et al.</i> (2000) "Natural and Designer Binding Sites Made by Phage Display Technology," <i>Immunology Today</i> 21(8): 371-378.	
	C31	Hopp <i>et al.</i> (1983) "A Computer Program For Predicting Protein Antigenic Determinants," <i>Molecular Immunology</i> 20(4): 483-489.	
	C32	International Search Report for PCT/US2003/014846, mailed on 11/30/2004 (2 pages).	
	C33	International Search Report for PCT/US2004/038283, mailed on 12/22/2005 (6 pages).	
	C34	International Search Report for PCT/US2005/003634, mailed on 09/15/2005 (3 pages).	
	C35	Kuruvilla <i>et al.</i> (2002) "Dissecting Glucose Signaling with Diversity-Oriented Synthesis and Small-Molecule Microarrays," <i>Nature</i> 416: 653-657.	
	C36	Kyte <i>et al.</i> (1982) "A Simple Method for Displaying the Hydrophobic Character of a Protein," <i>J. Mol. Biol.</i> 157: 105-132.	
	C37	Lesko <i>et al.</i> (2001) "Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, Strategies," <i>Annu. Rev. Pharmacol. Toxicol.</i> 41: 347-366.	
	C38	Li (2000) "Applications of Display Technology in Protein Analysis," <i>Nature Biotechnology</i> 18: 1251-1256.	
	C39	Lizardi <i>et al.</i> (1998) "Mutation Detection and Single Molecule Counting Using Isothermal Rolling Circle Amplification," <i>Mat. Genet.</i> 19: 225-232.	
	C40	Maggio (1980) <i>Enzyme-immunoassay</i> , pgs. 53-70.	

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/712,425		
		Filing Date	November 13, 2003		
		First Named Inventor	Lee		
		Art Unit	1631		
		Examiner Name	Lin, Jerry		
Sheet	3	of	3	Attorney Docket Number	EPT-001C1


C41	Mariani <i>et al.</i> (1987) "Immunogenicity of a Free Synthetic Peptide: Carrier Conjugation Enhances Antibody Affinity for the Native Protein," <i>Molecular Immunology</i> 24(3): 297-303.	
C42	Marks <i>et al.</i> (1992) "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>Bio/Technology</i> 10: 779-783.	
C43	Michaud <i>et al.</i> (2003) "Analyzing Antibody Specificity with Whole Proteome Microarrays," <i>Nat. Biotech.</i> 21(12) 1509-12 (e-publication 11/9/03).	
C44	Nelson <i>et al.</i> (2000) "Demystified... Monoclonal Antibodies," <i>J. Clin. Pathol.: Mol. Pathol.</i> 53: 111-117.	
C45	Ohlin <i>et al.</i> (1996) "Light Chain Shuffling of a High Affinity Antibody Results in a Drift in Epitope Recognition," <i>Molecular Immunology</i> 33(1): 47-56.	
C46	Rosenkranz (2003) "Biomarkers and Surrogate Endpoints in Clinical Drug Development," <i>Applied Clinical Trials</i> , pgs. 30-34, 40.	
C47	Schweitzer <i>et al.</i> (2002) "Multiplexed Protein Profiling on Microarrays by Rolling-Circle Amplification," <i>Nat. Biotechnol.</i> 20: 359-365.	
C48	Scrivener <i>et al.</i> (2003) "Peptidomics: A New Approach to Affinity Protein Microarrays," <i>Proteomics</i> 3: 122-128.	
C49	Shea <i>et al.</i> (1993) "Immunologic Detection and Measurement of Glycated Apolipoprotein B with Site Specific Monoclonal Antibodies," <i>J. Immunol. Methods</i> 162(1): 85-95.	
C50	Soderlind <i>et al.</i> (1999) "Complementary-Determining Region (CDR) Implantation: A Theme of Recombination," <i>Immunotechnology</i> 4: 279-285.	
C51	Soderlind <i>et al.</i> (2000) "Recombining Germline-Derived CDR Sequences for Creating Diverse Single-Framework Antibody Libraries," <i>Nature Biotechnology</i> 18: 852-856.	
C52	Soloviev <i>et al.</i> (2003) "Combinatorial Peptidomics: A Generic Approach for Protein Expression Profiling," <i>J. of Nanobiotechnology</i> 1: 1-19.	
C53	Vlatakis <i>et al.</i> (1993) "Drug Assay Using Antibody Mimics Made by Molecular Imprinting," <i>Nature</i> 361: 645-647.	
C54	Weckwerth (2003) "Metabolomics in Systems Biology," <i>Annu. Rev. Plant Biol.</i> 54: 669-689.	
C55	Werkmeister <i>et al.</i> (1991) "Multiple Antigenic Determinants on Type III Collagen," <i>Biochem. J.</i> 274: 895-898.	

LIBC/2851039.1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/712,425

Attorney Docket No.: EPT-001C1

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on October 3, 2006
Date

Signature

Randall D. Morin

Typed or printed name of person signing Certificate

58,312
Registration Number, if applicable

(617) 570-1000
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

- Transmittal Form (1 page)
- Fee Transmittal (1page)
- Supplemental Information Disclosure Statement (2 pages)
- PTO Form SB/08a/b citing references A6-A31, B4-B11, and C14-C55 (3 pages)
- Copies of cited references B4-B11 and C14-C54
- Check in the amount of \$180.00
- Return Receipt Postcard

2851186